Alaunos Therapeutics director granted stock & options – Form 4 details

Rhea-AI Filing Summary

Form 4 filing for Alaunos Therapeutics, Inc. (TCRT) discloses that director Robert W. Postma received new equity awards on July 3, 2025.

• Restricted stock units (RSUs): 4,050 shares of common stock granted at $0.00 cost and vested immediately, increasing his direct holding to 33,133 shares.
• Stock options: Option to purchase 6,400 shares at an exercise price of $5.00 per share, expiring July 3, 2035. One-twelfth of the option vests monthly starting July 3, 2025; any remaining unvested portion fully vests just before the 2026 annual meeting.
• Indirect holdings: 62,416 shares held through WaterMill Asset Management Corp. and 24 shares in a spouse’s IRA.

The transactions are incentive-based grants rather than market purchases or sales, so they do not immediately affect public float or cash flows. However, they modestly increase insider ownership and further align the director’s interests with shareholders.

Positive

• Increased insider alignment: Director now holds 33,133 shares directly, plus options, which may strengthen long-term shareholder alignment.

Negative

• None.

Insights

Securities Analyst

TL;DR – Routine incentive grant; neutral impact on valuation.

The filing shows a customary annual equity package: 4,050 RSUs and 6,400 options at $5. These instruments represent <1% of shares outstanding and involve no cash outlay by the company now. Because the awards vest over time, they create minimal immediate dilution yet strengthen insider alignment. No open-market buying or selling occurred, so signaling value is limited. Overall, this is standard governance practice, not a catalyst for the stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Postma Robert W

(Last) (First) (Middle)

C/O ALAUNOS THERAPEUTICS, INC.

2617 BISSONNET ST, SUITE 233

(Street)

HOUSTON TX 770005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/03/2025		A		4,050	A	$0.00	33,133(1)	D
Common Stock								24	I	By spouse's IRA
Common Stock								62,416	I	By WaterMill Asset Management Corp.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5	07/03/2025		A		6,400		(3)	07/03/2035	Common Stock	6,400	$0.00	6,400	D

Explanation of Responses:

1. Represents a grant of restricted stock units (RSUs) which immediately vested upon grant. After the reported acquisition of the RSUs, the reporting person owned in aggregate 33,133 shares of common stock (29,083 previously owned shares, plus the instant grant of 4,034 RSUs).

2. The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill.

3. One-twelfth of the Option vests each month on the monthly anniversary of July 3, 2025, with any amount that remains unvested on the date immediately preceding the Company's 2026 annual general meeting of stockholders vesting thereon.

	/s/ Melinda Lackey, Attorney-in-Fact	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Alaunos Therapeutics (TCRT) shares did Robert W. Postma acquire?

He received 4,050 RSUs that vested immediately, raising his direct ownership to 33,133 shares.

What stock options were granted to the Alaunos director?

Postma was granted 6,400 options with a $5.00 exercise price, expiring on July 3, 2035.

Does the Form 4 indicate any open-market purchases or sales of TCRT stock?

No. The filing only reports equity grants (RSUs and options) at no cost, not market transactions.

What are Robert Postma’s indirect holdings in TCRT after the grant?

He indirectly controls 62,416 shares via WaterMill Asset Management and 24 shares in his spouse’s IRA.

When will the newly granted TCRT options vest?

One-twelfth vests monthly beginning July 3, 2025; any remainder vests just before the 2026 annual meeting.